Loading…
Prothena Corporation plc is projected to rise to $11.73 by 2027, a +17% move from its current price of $10.03. PRTA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $9.75 | $10.03 | $10.32 | +0.02% |
| May 30 | $9.64 | $10.03 | $10.45 | +0.03% |
| May 31 | $9.55 | $10.03 | $10.54 | +0.05% |
| Jun 1 | $9.48 | $10.04 | $10.63 | +0.06% |
| Jun 2 | $9.42 | $10.04 | $10.70 | +0.08% |
| Jun 3 | $9.36 | $10.04 | $10.77 | +0.10% |
| Jun 4 | $9.31 | $10.04 | $10.83 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.31 | $10.04 | $10.83 | +0.11% |
| Week 2 | $9.03 | $10.05 | $11.19 | +0.23% |
| Week 3 | $8.83 | $10.06 | $11.47 | +0.34% |
| Week 4 | $8.66 | $10.08 | $11.72 | +0.45% |
| Week 5 | $8.52 | $10.09 | $11.94 | +0.56% |
| Week 6 | $8.39 | $10.10 | $12.15 | +0.68% |
| Week 7 | $8.28 | $10.11 | $12.35 | +0.79% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Prothena Corporation plc (PRTA) is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. The company was incorporated in 2012 and is based in Dublin, Ireland.
Its product pipeline includes prasinezumab, an investigational humanized monoclonal antibody in Phase 3 for the treatment of Parkinson's disease and other synucleinopathies; coramitug, in Phase 3 for transthyretin amyloidosis; BMS-986446, an anti-tau antibody in Phase 2 to treat Alzheimer's disease; PRX019, in Phase 1 for neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs such as TDP-43 CYTOPE for the treatment of ALS and PRX012, in Phase 1 for Alzheimer's disease, as well as PRX012-TfR in preclinical development for Alzheimer's disease. It has a license, development, and commercialization agreement with Roche to develop and commercialize antibodies targeting alpha-synuclein (including prasinezumab) and a master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau and TDP-43.
Prothena Corporation plc is a biotechnology company focused on therapies for protein dysregulation with a portfolio of antibody programs and collaborations. It operates in the healthcare sector, with a global focus supported by multiple clinical-stage assets and strategic partnerships. The current price and market position reflect a niche, late-stage clinical biotech profile with significant upside potential reflected in its multi-year forecast.
A major floor 22.6% below — a decisive break under it would weaken the trend.
The nearest floor, 9.6% below — buyers have tended to step in here.
The nearest ceiling, 14.8% above — a clean break opens room to run.
A major ceiling 26.1% above — clearing it would confirm fresh momentum.
Key PRTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.74 | Buy | $9.84 | Buy |
| MA 10 | $9.66 | Buy | $9.82 | Buy |
| MA 20 | $10.13 | Sell | $9.98 | Buy |
| MA 50 | $10.07 | Sell | $10.01 | Buy |
| MA 100 | $9.63 | Buy | $9.84 | Buy |
| MA 200 | $9.59 | Buy | $9.99 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.91 | Neutral |
| Stoch RSI (14) | 85.14 | Sell |
| CCI (20) | -11.48 | Neutral |
| Williams %R (14) | -42.17 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -6.52 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 57.83 | Neutral |
| TRIX (15) | -0.22 | Sell |
| Awesome (5,34) | -0.64 | Sell |
| Ultimate (7,14,28) | 50.33 | Neutral |
| Momentum (10) | 0.60 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 9.98 | Buy |
| ADX (14) | 15.81 | Neutral |
| ATR (14) | 0.26 | Info |
The stock shows a NEUTRAL sentiment with an RSI of 50. The 50-day simple moving average is $10.03 and the 200-day simple moving average is $9.57, placing near-term price action around the $9.07 support and $11.51 resistance levels.
Over the past 30 days, the price has moved within a range of $8.07 to $11.97, indicating a relatively tight trading band around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.35 | $10.03 | $14.62 | 0% | Neutral | |
| $9.26 | $11.73 | $15.76 | +17% | Neutral | |
| $9.90 | $12.90 | $17.99 | +29% | Bullish | |
| $10.41 | $13.90 | $19.95 | +39% | Bullish | |
| $10.33 | $14.09 | $20.74 | +40% | Bullish | |
| $11.50 | $15.98 | $24.04 | +59% | Bullish | |
| $13.77 | $19.48 | $29.88 | +94% | Bullish | |
| $15.68 | $22.57 | $35.23 | +125% | Bullish | |
| $15.92 | $23.29 | $36.95 | +132% | Bullish | |
| $15.73 | $23.38 | $37.66 | +133% | Bullish | |
| $22.94 | $36.59 | $62.79 | +265% | Bullish | |
| $36.36 | $65.60 | $123.43 | +554% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $8.35 | $10.03 | $11.83 | +0.00% |
| June 2026 | $8.64 | $10.16 | $12.23 | +1.25% |
| July 2026 | $8.58 | $10.18 | $12.43 | +0.23% |
| August 2026 | $8.94 | $10.67 | $13.18 | +4.88% |
| September 2026 | $9.25 | $11.11 | $13.84 | +4.07% |
| October 2026 | $9.16 | $11.06 | $13.88 | -0.46% |
| November 2026 | $9.16 | $11.12 | $14.05 | +0.51% |
| December 2026 | $9.43 | $11.49 | $14.62 | +3.39% |
Click any year to see its month-by-month PRTA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Prothena Corporation plc's 2026 outlook centres on $10.03, within a $8.35 to $14.62 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PRTA could reach as high as $15.76, with a base case around $11.73 and support toward $9.26 — roughly +17% from $10.03. A consolidation phase looks the most probable path here.
Expect PRTA to range from $9.90 to $17.99 through 2028. The $12.90 average target implies a +29% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The PRTA price prediction for 2029 points to an average of $13.90 (low $10.41, high $19.95) — a potential gain of +39% on today's $10.03. Buyers look set to stay in control over this stretch.
In 2030, PRTA is projected to trade between $10.33 and $20.74, averaging $14.09 — a potential gain of +40% from today's $10.03. That is up +1% on the projected 2029 average. Momentum favours further upside here.
Prothena Corporation plc's 2031 outlook centres on $15.98, within a $11.50 to $24.04 range. That is up +13% on the projected 2030 average. That marks a +59% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PRTA could reach as high as $29.88, with a base case around $19.48 and support toward $13.77 — roughly +94% from $10.03. Momentum favours further upside here.
Expect PRTA to range from $15.68 to $35.23 through 2033. The $22.57 average target implies a +125% move from current prices. That is up +16% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PRTA price prediction for 2034 points to an average of $23.29 (low $15.92, high $36.95) — a potential gain of +132% on today's $10.03. Momentum favours further upside here.
In 2035, PRTA is projected to trade between $15.73 and $37.66, averaging $23.38 — a potential gain of +133% from today's $10.03. That is up 0% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Prothena Corporation plc's 2040 outlook centres on $36.59, within a $22.94 to $62.79 range. That is up +57% on the projected 2035 average. That marks a +265% change versus current levels. Momentum favours further upside here.
By 2050, PRTA could reach as high as $123.43, with a base case around $65.60 and support toward $36.36 — roughly +554% from $10.03. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRTA today (≈ 99.700897 PRTA) could be worth
$6,540.18
+$5,540.18 (+554%) by 2050 · US Dollar
Based on the average projected PRTA price of $65.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRTAwould be worth at today's price.
$1,000 invested in PRTA on May 27, 2025 (≈ 218.340615 PRTA) would be worth
$2,189.96
+$1,189.96 (+119.0%) today · 2.19× · US Dollar
Based on a PRTA entry price of $4.58 vs. today's $10.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.35 | $1,072.73 | +7.3% |
| 1 month ago | $10.79 | $929.56 | -7.0% |
| 3 months ago | $8.64 | $1,160.88 | +16.1% |
| 6 months ago | $10.75 | $933.02 | -6.7% |
| 1 year ago | $4.58 | $2,189.96 | +119.0% |
| All time (5.0y) ago | $27.44 | $365.52 | -63.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRTA forecast.
Our base-case forecast reaches $20.00 around 2033.
Implied market cap at $20.00: $1.05B
The multi-year forecast shows a progressive rise in expected prices. In 2026 the average forecast is $9.83, with a projected range from $8.35 to $14.50 and an implied outlook of neutral sentiment. By 2027, the average forecast rises to $11.41 with a max of $15.45 and a bullish-to-neutral tilt on the path ahead (ROI 16.1%).
The path continues higher into 2028 with an average of $12.65 (max $17.79, ROI 28.7%) and 2029 with an average of $13.61 (max $19.73, ROI 38.4%).
By 2030, the average forecast is $13.54 with a min of $9.84 and a max of $20.14, yielding an ROI of 37.7% and a bullish sentiment. The forecast strengthens further through 2031–2035, with 2031 at $15.58, 2032 at $19.13, 2033 at $21.93, 2034 at $22.75, and 2035 at $22.76, all carrying a bullish outlook. Looking ahead to 2040, the average forecast jumps to $35.82 (max $62.44, ROI 264.4%) and, by 2050, to $63.53 on average (max $121.78, ROI 546.3%), with bullish sentiment throughout.
These figures are estimates and not guarantees. They should be interpreted with caution, as actual results depend on clinical outcomes, regulatory milestones, and market factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $13.54, with a min of $9.84 and a max of $20.14, and an expected ROI of 37.7% with a bullish outlook.
Forecasts show gradual price increases from 2026 to 2035, with higher potential by 2040 ($35.82 average) and by 2050 ($63.53 average) and ROI up to 546.3%. These numbers are estimates, not guarantees.
Yes, the 2050 forecast lists an average price of $63.53 and a max of $121.78, with a long-term bullish outlook.
The 30-day range is $8.07 to $11.97, RSI 50, SMA50 $10.03, SMA200 $9.57, with support at $9.07 and resistance at $11.51.
Current price is $9.83 and market cap is $514.63M.
Prothena Corporation plc Community Discussion
0Share your Prothena Corporation plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.